Product description
One-Step Solid-Phase Synthesis Preloaded Long-Acting Side Chain Monomer for Semaglutide
The long-acting glucose-lowering activity of Semaglutide relies on the C18 stearic acid + γ-Glu + bis-AEEA structure at the Lys26 position. The C18 lipid chain reversibly binds to serum albumin to extend the in vivo half-life, while the bis-AEEA polyether spacer balances lipophilicity and hydrophilicity.
In conventional processes, Semaglutide synthesis is typically performed in two steps: first assembling the unmodified Lys-containing peptide chain by solid-phase synthesis, followed by liquid-phase activation and grafting of the lipid side chain. This approach often results in significant coupling loss and the formation of over-modified impurities. This product preloads the complete lipid side chain onto the lysine side chain, enabling one-step insertion at position 26 during solid-phase peptide synthesis. It eliminates the need for separate side-chain activation and liquid-phase grafting, significantly improving overall API yield and simplifying purification. It is a mainstream high-efficiency building block for large-scale industrial solid-phase production of Semaglutide.
Orthogonal Stepwise Deprotection Compatible with Standard Fmoc Workflows
The N-terminal Fmoc group can be gently removed using piperidine without affecting the side-chain OtBu protecting groups. All tert-butyl ester protecting groups are removed simultaneously during the final TFA cleavage, releasing the complete unprotected lipid-modified side chain in one step. This strategy is fully compatible with the Boc/Trt/OtBu cleavage systems used for other Semaglutide fragments and requires no segmented deprotection.
No Pharmacological or Cosmetic Activity
This molecule contains an Fmoc aromatic fluorenyl group, a long C18 hydrophobic carbon chain, and multiple OtBu tert-butyl ester protecting groups. Due to its large molecular size, it cannot penetrate cell membranes or the skin barrier. Direct administration or topical application may leave residual fluorenyl and tert-butyl ester decomposition impurities, posing potential mucosal or skin irritation risks. Therefore, it is not a pharmaceutical formulation or a compliant cosmetic ingredient.
Universal Integrated Lysine Building Block for C18 Lipid-Modified GLP Peptides
In addition to Semaglutide, this product can be used for the solid-phase synthesis of other long-acting GLP-1 peptides modified with C18 stearic acid. Its integrated preloaded side-chain design addresses the challenges of low coupling efficiency and high impurity formation in stepwise long hydrophobic lipid-chain conjugation, significantly reducing industrial production costs for long-acting GLP peptides.
This product is supplied exclusively as an industrial intermediate for pharmaceutical API synthesis. It is intended solely for factory-scale solid-phase peptide synthesis and is not suitable for direct injection, oral administration, or topical application.